Goto, KoichiKoichiGotoGoto, YasushiYasushiGotoKubo, ToshioToshioKuboNinomiya, KiichiroKiichiroNinomiyaKim, Sang-WeSang-WeKimPlanchard, DavidDavidPlanchardAhn, Myung-JuMyung-JuAhnSmit, Egbert FEgbert FSmitde Langen, Adrianus JohannesAdrianus Johannesde LangenPérol, MauriceMauricePérolPons-Tostivint, ElvireElvirePons-TostivintNovello, SilviaSilviaNovelloHayashi, HidetoshiHidetoshiHayashiShimizu, JunichiJunichiShimizuKim, Dong-WanDong-WanKimKuo, Chih-HsiChih-HsiKuoCHIH-HSIN YANGPereira, KalineKalinePereiraCheng, Fu-ChihFu-ChihChengTaguchi, AyumiAyumiTaguchiCheng, YingkaiYingkaiChengFeng, WenqinWenqinFengTsuchihashi, ZentaZentaTsuchihashiJänne, Pasi APasi AJänne2023-11-292023-11-292023-11-010732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/637413Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2-mutant (HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non-small-cell lung cancer (mNSCLC).en[SDGs]SDG3journal article10.1200/JCO.23.01361376943472-s2.0-85173250493https://api.elsevier.com/content/abstract/scopus_id/85173250493